P04.02 A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies

Cancer Immunotherapy
DOI: 10.1136/jitc-2020-itoc7.71 Publication Date: 2020-10-01T09:36:14Z
ABSTRACT
<h3>Background</h3> Virus-based vaccines and appropriate costimulation potently enhance antigen-specific T cell immunity against cancer. In the present study, we exploit both innate adaptive immune responses triggered by a novel recombinant modified vaccinia virus Ankara (rMVA) encoding Tumor-Associated Antigen (TAA) costimulatory CD40L solid tumors in combination regimes to overcome tumor-induced resistance immunotherapy. <h3>Material Methods</h3> Subcutaneous murine were induced C57BL/6 or Balb/c mice using syngeneic tumor lines. When established (60–80 mm<sup>3</sup>) intravenously injected with rMVA-CD40L. Tumor growth monitoring analysis was performed. <h3>Results</h3> Therapeutic treatment rMVA-CD40L resulted control of several independent models. This antitumor effect based on generation non-exhausted, systemic tumor-specific cytotoxic CD8<sup>+</sup> cells that essential for therapeutic efficacy. Strikingly, also strong NK activation enhanced cytotoxicity. Moreover, targeting antibodies increased relied Fcγ receptor-expressing as well cells. <h3>Conclusion</h3> We describe translationally relevant synergy between viral vaccination costimulation. show strengthened when rMVA-CD40L-induced mechanisms are exploited combining immunotherapeutic regimes, such TAA antibodies. finding could have direct positive impact regimens where be employed. <h3>Disclosure Information</h3> <b>M. Hinterberger:</b> A. Employment (full part-time); Significant; Bavarian Nordic. <b>J. Medina-Echeverz:</b> Testori:</b> Geiger:</b> <b>R. Giessel:</b> <b>B. Bathke:</b> Kassub:</b> <b>F. Gräbnitz:</b> <b>G. Fiore:</b> <b>S. Wennier:</b> <b>P. Chaplin:</b> Suter:</b> <b>H. Hochrein:</b> Lauterbach:</b>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (1)